Review
Nature Reviews Cancer 5, 459-467 (June 2005) | doi:10.1038/nrc1630
Immunotherapy for pancreatic cancer — science driving clinical progress
Dan Laheru1 & Elizabeth M. Jaffee2 About the authors
Abstract
The identification of key signalling pathways involved in immune-system regulation, along with the development of early pancreatic tumours in mouse models have provided new opportunities for pancreatic cancer treatment and prevention. Immunotherapy for pancreatic cancer is one approach that is at a crucial crossroads, as therapeutics that are designed to target pancreatic-cancer-associated antigens and regulatory signalling molecules are entering clinical trials.
- View At a Glance
Author affiliations
- Department of Medical Oncology, Room G89, Baltimore, Maryland 21231-1000, USA.
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Bunting-Blaustein Cancer Research Building, Room 4M07, Baltimore, Maryland 21231, USA.
Correspondence to: Elizabeth M. Jaffee2 Email: ejaffee@jhmi.edu
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Free radical-mediated damage to barrier function is not associated with altered brain morphology in high-altitude headacheJournal of Cerebral Blood Flow & Metabolism Original Article